Immunic, Inc. (IMUX)
16.50
0.00 (0.00%)
USD |
NASDAQ |
Aug 24, 16:00
16.50
0.00 (0.00%)
After-Hours: 20:00
Immunic Enterprise Value : 70.60M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 70.60M |
| August 20, 2026 | 65.15M |
| August 19, 2026 | 69.92M |
| August 18, 2026 | 76.06M |
| August 17, 2026 | 64.19M |
| August 14, 2026 | 64.60M |
| August 13, 2026 | 71.69M |
| August 12, 2026 | 62.83M |
| August 11, 2026 | 56.69M |
| August 10, 2026 | 37.86M |
| August 07, 2026 | 40.59M |
| August 06, 2026 | 43.86M |
| August 05, 2026 | 36.63M |
| August 04, 2026 | 37.17M |
| August 03, 2026 | 37.86M |
| July 31, 2026 | 36.08M |
| July 30, 2026 | 36.36M |
| July 29, 2026 | 23.53M |
| July 28, 2026 | 27.49M |
| July 27, 2026 | 33.90M |
| July 24, 2026 | 28.17M |
| July 23, 2026 | 40.31M |
| July 22, 2026 | 51.64M |
| July 21, 2026 | 52.18M |
| July 20, 2026 | 50.14M |
| Date | Value |
|---|---|
| July 17, 2026 | 52.32M |
| July 16, 2026 | 50.55M |
| July 15, 2026 | 51.50M |
| July 14, 2026 | 45.91M |
| July 13, 2026 | 45.22M |
| July 10, 2026 | 47.00M |
| July 09, 2026 | 47.13M |
| July 08, 2026 | 47.00M |
| July 07, 2026 | 55.05M |
| July 06, 2026 | 48.23M |
| July 02, 2026 | 47.41M |
| July 01, 2026 | 47.54M |
| June 30, 2026 | 55.18M |
| June 29, 2026 | 23.70M |
| June 26, 2026 | 22.20M |
| June 25, 2026 | 19.07M |
| June 24, 2026 | 14.16M |
| June 23, 2026 | 19.07M |
| June 22, 2026 | 14.71M |
| June 18, 2026 | 7.217M |
| June 17, 2026 | 7.217M |
| June 16, 2026 | 0.5428M |
| June 15, 2026 | 4.629M |
| June 12, 2026 | 2.586M |
| June 11, 2026 | -8.175M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 4.195B |
| Sionna Therapeutics, Inc. | 35.96M |
| Alnylam Pharmaceuticals, Inc. | 31.27B |
| Anika Therapeutics, Inc. | 278.32M |
| Savara, Inc. | 1.006B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -34.10M |
| Total Expenses (Quarterly) | 34.10M |
| EPS Diluted (Quarterly) | -0.8021 |
| Earnings Yield | -29.13% |
| Normalized Earnings Yield | -29.13 |